Earnings Call Summary | Legend Biotech(LEGN.US) Q1 2024 Earnings Conference
Earnings Call Summary | Legend Biotech(LEGN.US) Q1 2024 Earnings Conference
The following is a summary of the Legend Biotech Corporation (LEGN) Q1 2024 Earnings Call Transcript:
以下是联想生物科技公司(LEGN)2024年第一季度财报电话会议记录的摘要:
Financial Performance:
财务业绩:
Legend Biotech reported net trade sales of $157 million for the first quarter of 2024, marking a 100% year-on-year increase in sales from CARVYKTI.
There was a slight decrease from $159 million in Q4 2023 due to order timing and manufacturing testing.
Research and development expenses increased to $101 million in Q1 2024, up from $84.9 million in Q1 2023.
As of March 2024, Legend Biotech had a cash balance of $1.3 billion.
Company expects to attain operating profit by 2026 and may consider additional capital raises depending on business development.
联想生物科技报告称,2024年第一季度的净贸易销售额为1.57亿美元,标志着CARVYKTI的销售额同比增长了100%。
由于订单时间和制造测试,与2023年第四季度的1.59亿美元相比略有下降。
研发费用从2023年第一季度的8,490万美元增加到2024年第一季度的1.01亿美元。
截至2024年3月,联想生物的现金余额为13亿美元。
公司预计到2026年将实现营业利润,并可能根据业务发展考虑额外筹集资金。
Business Progress:
业务进展:
CARVYKTI received approval from major health regulatory bodies, widening its potential patient base to 80,000 across significant markets.
The company plans to double production capacity for CARVYKTI by the end of 2024 and reach 10,000 patient slots capacity by the end of 2025.
The number of US hospitals certified to administer CARVYKTI has increased to 72, expanding its reach into the community.
Trials for triple targeted CAR-T treatment are underway in China, with an expansion into autoimmune disease indications in the US planned.
Legend Biotech plans to increase capital investment to support business expansion, indicating positive business progress.
CARVYKTI获得了主要卫生监管机构的批准,将其在重要市场的潜在患者基础扩大到8万人。
该公司计划到2024年底将CARVYKTI的产能翻一番,到2025年底达到10,000个患者席位的产能。
获得CARVYKTI认证的美国医院数量已增加到72家,从而将其覆盖范围扩大到社区。
中国正在进行三靶向CAR-T治疗的试验,并计划在美国扩大到自身免疫性疾病的适应症。
Legend Biotech计划增加资本投资以支持业务扩张,这表明业务取得了积极进展。
More details: Legend Biotech IR
更多详情: 传奇生物科技 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。